Anika Therapeutics, Inc. (ANIK) Tops Q1 Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.95 -3.85%
Revenue Growth %: +5.9%
Financial Fact:
Selling, general & administrative: 4.28M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: +5.9%
Financial Fact:
Selling, general & administrative: 4.28M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q1 EPS of $0.97, $0.72 better than the analyst estimate of $0.25. Revenue for the quarter came in at $34 million versus the consensus estimate of $16.03 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Top oil & gas exploration stocks, according to Mizuho
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
